Tuesday, April 13, 2010 1:26:51 PM
Note - It should be seen that there are unknown variations from this initial filing. Namely, it now appears that GAGI will acquire Regen Acquistions before the official merger.
"Our Biotechnology sector’s flagship acquisition is Regenetech, Inc., a Houston based bio-medical research and licensing company with which we have entered into a merger agreement. Under the Merger Agreement, which is subject to the approval of two-thirds of the shareholders of Regenetech. Regenetech will merge with our wholly-owned Texas subsidiary, Regen Acquisitions Corp., with Regenetech as the surviving corporation, and a wholly-owned subsidiary of the Company. Assuming approval of the necessary two-thirds vote of the Regenetech shareholders, which is currently underway, the merger will close immediately following the effective date of our registration statement and the initial public offering. The negotiated value of the acquisition is $100,000,000, to be paid for with stock of the Company exchanged for all of the stock of Regenetech, based on the final IPO price for Healthcare of Today common stock at the effective date of the registration statement, divided into the net acquisition value of $100,000,000 reduced by outstanding debts and liabilities of Regenetech. The maximum number of shares of the Company to be issued, at the expected IPO price of $18.00 per share, would be 5,555,555 common shares assuming no liabilities of Regenetech at the date of closing. The Company has agreed as part of the transaction to register 30 percent of the shares issued in the registration statement or up to 1,666,666 shares."
It isn't true without a link! -->
http://ipo.nasdaq.com/edgar_conv_html%5C2009%5C07%5C17%5C0001440242-09-000005.html
Recent EUBG News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:02:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2023 09:00:08 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:02:50 PM
- Form SPDSCL - SEC Specialized Disclosure • Edgar (US Regulatory) • 07/20/2023 04:55:56 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM